drugset / Trial / NCT07838779
An OLIP Study (Open Label Individual Patient) of Nusinersen in a Participant With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With Nusinersen
Not yet recruiting
1 enrolled
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
NaSingle-groupOpen-labelTreatment
Summary
This study is an open label individual patient study of the drug Nusinsersen.
Timeline
- Start
- 2026-09-17
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nusinersen | Antisense oligonucleotide | 28 mg | Intrathecal |